OhkumaTIwaseMFujiiH, et al. Dose- and time-dependent association of smoking and its cessation with glycemic control and insulin resistance in male patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. PLoS One. 2015;10(3):e0122023.
2.
PengKChenGLiuC, et al. REACTION Study Group. Association between smoking and glycemic control in diabetic patients: results from the Risk Evaluation of cAncers in Chinese diabeTic Individuals: A lONgitudinal (REACTION) study. J Diabetes. 2018;10(5):408-418.
3.
TelitiMCogniGSacchiL, et al. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients. Diab Vasc Dis Res. 2018;15(5):424-432.
4.
SiuAL; U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventa-tive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(8):622-635.
5.
BaruaRSRigottiNABenowitzNL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment. J Am Coll Cardiol. 2018;72:3332-3365.
6.
FioreMCRobertoCBakerT, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
AubinHJLuguiensABerlinI.Pharmacotherapy for smoking cessation: pharmacology principles and clinical practice. Br J Clin Pharmacol. 2014;77(2):324-336.
9.
AnthenelliRMBenowitzNLWestR, et al. Neuropsychi-atric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507-2520.
